Arcticzymes Technologies ASA (AZT) - Total Assets

Latest as of June 2026: Nkr379.11 Million NOK ≈ $39.89 Million USD

Based on the latest financial reports, Arcticzymes Technologies ASA (AZT) holds total assets worth Nkr379.11 Million NOK (≈ $39.89 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Arcticzymes Technologies ASA - Total Assets Trend (2002–2025)

This chart illustrates how Arcticzymes Technologies ASA's total assets have evolved over time, based on quarterly financial data. Also see AZT market cap overview for the company's overall valuation and market capitalisation.

Arcticzymes Technologies ASA - Asset Composition Analysis

Current Asset Composition (December 2025)

Arcticzymes Technologies ASA's total assets of Nkr379.11 Million consist of 85.2% current assets and 14.8% non-current assets. Review Arcticzymes Technologies ASA (AZT) financial obligations to assess the company's total debt and financial obligations.

Asset Category Amount (NOK) % of Total Assets
Cash & Equivalents Nkr187.78 Million 52.0%
Accounts Receivable Nkr21.88 Million 6.1%
Inventory Nkr16.16 Million 4.5%
Property, Plant & Equipment Nkr16.78 Million 4.6%
Intangible Assets Nkr34.06 Million 9.4%
Goodwill Nkr0.00 0.0%

Asset Composition Trend (2002–2025)

This chart illustrates how Arcticzymes Technologies ASA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Arcticzymes Technologies ASA stock price for real-time trading data and today's change.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Arcticzymes Technologies ASA's current assets represent 85.2% of total assets in 2025, an increase from 60.1% in 2002.
  • Cash Position: Cash and equivalents constituted 52.0% of total assets in 2025, up from 33.0% in 2002.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 8.0% in 2002.
  • Asset Diversification: The largest asset category is cash and equivalents at 52.0% of total assets.

Arcticzymes Technologies ASA Competitors by Total Assets

Key competitors of Arcticzymes Technologies ASA based on total assets are shown below.

Company Country Total Assets
Ascendis Pharma AS
F:A71
Germany €2.00 Billion
Halozyme Therapeutics Inc
NASDAQ:HALO
USA $2.22 Billion
Abivax SA American Depositary Shares
NASDAQ:ABVX
USA $547.14 Million
Tubize-Fin
BR:TUB
Belgium €1.99 Billion
Kailera Therapeutics, Inc. Common Stock
NASDAQ:KLRA
USA $1.21 Billion
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
USA $512.24 Million
Beijing Hotgen Biotech Co Ltd
SHG:688068
China CN¥3.21 Billion
Wuhan Keqian Biology Co Ltd
SHG:688526
China CN¥4.75 Billion

Arcticzymes Technologies ASA - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 17.68 15.90 11.10
Quick Ratio 16.86 15.02 10.77
Cash Ratio 0.00 9.42 9.87
Working Capital Nkr295.22 Million Nkr271.76 Million Nkr191.26 Million

Arcticzymes Technologies ASA - Advanced Valuation Insights

This section examines the relationship between Arcticzymes Technologies ASA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 3.05
Latest Market Cap to Assets Ratio 0.30
Asset Growth Rate (YoY) 5.0%
Total Assets Nkr361.41 Million
Market Capitalization $109.63 Million USD

Valuation Analysis

Below Book Valuation: The market values Arcticzymes Technologies ASA's assets below their book value (0.30x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Arcticzymes Technologies ASA's assets grew by 5.0% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Arcticzymes Technologies ASA (2002–2025)

The table below shows the annual total assets of Arcticzymes Technologies ASA from 2002 to 2025.

Year Total Assets Change
2025-12-31 Nkr361.41 Million
≈ $38.03 Million
+4.98%
2024-12-31 Nkr344.26 Million
≈ $36.23 Million
+1.46%
2023-12-31 Nkr339.32 Million
≈ $35.71 Million
+6.36%
2022-12-31 Nkr319.04 Million
≈ $33.57 Million
+12.29%
2021-12-31 Nkr284.11 Million
≈ $29.90 Million
+28.03%
2020-12-31 Nkr221.91 Million
≈ $23.35 Million
+185.93%
2019-12-31 Nkr77.61 Million
≈ $8.17 Million
+14.11%
2018-12-31 Nkr68.02 Million
≈ $7.16 Million
+10.27%
2017-12-31 Nkr61.68 Million
≈ $6.49 Million
-28.13%
2016-12-31 Nkr85.83 Million
≈ $9.03 Million
-15.08%
2015-12-31 Nkr101.07 Million
≈ $10.64 Million
-9.05%
2014-12-31 Nkr111.13 Million
≈ $11.69 Million
+106.64%
2013-12-31 Nkr53.78 Million
≈ $5.66 Million
+66.83%
2012-12-31 Nkr32.24 Million
≈ $3.39 Million
-42.89%
2011-12-31 Nkr56.44 Million
≈ $5.94 Million
-18.17%
2010-12-31 Nkr68.98 Million
≈ $7.26 Million
-25.19%
2009-12-31 Nkr92.20 Million
≈ $9.70 Million
-50.90%
2008-12-31 Nkr187.77 Million
≈ $19.76 Million
-14.47%
2007-12-31 Nkr219.54 Million
≈ $23.10 Million
+77.41%
2006-12-31 Nkr123.75 Million
≈ $13.02 Million
-11.98%
2005-12-31 Nkr140.59 Million
≈ $14.79 Million
+140.00%
2004-12-31 Nkr58.58 Million
≈ $6.16 Million
-10.55%
2003-12-31 Nkr65.49 Million
≈ $6.89 Million
+757.74%
2002-12-31 Nkr7.63 Million
≈ $803.39K
--

About Arcticzymes Technologies ASA

OL:AZT Norway Biotechnology
Market Cap
$109.63 Million
Nkr1.04 Billion NOK
Market Cap Rank
#18941 Global
#169 in Norway
Share Price
Nkr20.40
Change (1 day)
+0.49%
52-Week Range
Nkr18.65 - Nkr30.90
All Time High
Nkr111.00
About

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids… Read more